Mirum Pharmaceuticals raised full-year revenue guidance to $660M-$680M after Q1 net sales rose to $114M.
Mirum Pharmaceuticals reported first-quarter 2026 net sales of $114 million for LIVMARLI, a 55% year-over-year increase. The company raised its full-year revenue guidance to $660 million-$680 million, citing strong demand in PFIC and steady growth in Alagille syndrome.
LIVMARLI’s performance outpaced prior-year results and exceeded consensus estimates. The updated guidance reflects continued commercial momentum and pipeline advancements, including positive data for volixibat in PSC and brelovitug in hepatitis delta.
Mirum also highlighted business development activity, adding zilurgisertib for FOP, while emphasizing financial strength and long-term value creation over near-term profitability.